HMGB1 是一种用于消化道癌症患者预后的新型免疫生物标志物。-猫眼课题宝

HMGB1 是一种用于消化道癌症患者预后的新型免疫生物标志物。

批准号：

23591963

负责人：

SUZUKI Nobuaki

金额：

$3.08万

依托单位：

Yamaguchi University

依托单位国家：

日本

项目类别：

Grant-in-Aid for Scientific Research (C)

财政年份：

2011

资助国家：

日本

项目状态：

已结题

起止时间：

2011 至 2013

来源：

https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591963/

关键词：

HMGB1 バイオマーカー NKG2D ULBP1 B7-H3 NKG2DL Toll like receptor 化学療法免疫療法 Toll like recepter

项目摘要

项目成果

SUZUKI Nobuaki的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

High mobility group box 1 (HMGB1) plays a role in many clinical conditions such as autoimmunity, acute ischemia-reperfusion injury, cardiovascular disease and cancer. HMGB1 is a nuclear protein and released from the apoptotic cells to activate cytotoxic T cells and antigen-presenting cells effectively. The aim of this study was to clarify HMGB1 is associated with recurrence or prognosis as a biomarker, and we performed immunohistochemistry of HMGB1 in resected specimen. We performed immunohistochemistry for 90 gastric cancer cases, 30 cases of colorectal cancer, and 10 cases as pancreatic cancer, the expression of HMGB1 in cancer tissues is a good prognostic factor in gastric cancer patients. B7-H3, NKG2D, NKG2DL are also stained, with a combination of expression of staining intensity, ULBP1/NKG2D interaction was suggested as good prognostic marker for the patients in gastric cancer.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文